TSE:5201Building
mRNA Heart Therapy Partnership Could Be a Game Changer for AGC (TSE:5201)
On November 19, 2025, Repair Biotechnologies announced a partnership with AGC Biologics to develop and manufacture a novel mRNA therapy aimed at reducing atherosclerotic plaques, a leading cause of heart attack and stroke globally.
This collaboration highlights a shift for mRNA technology, as AGC Biologics applies its expertise to chronic cardiovascular diseases beyond its previous work in infectious disease therapies.
We’ll explore how AGC Biologics’ expansion into chronic disease mRNA...